Skip to main content
. Author manuscript; available in PMC: 2010 May 15.
Published in final edited form as: Clin Cancer Res. 2009 May 5;15(10):3583–3590. doi: 10.1158/1078-0432.CCR-08-2917

Table 3. Clinical Outcomes.

Outcome Docetaxel N = 25 Docetaxel and bevacizumab N = 24
Surgical candidate 19 (76%) 19 (79%)
Breast conserving surgery 7 (37%) 1 (5%)
Modified radical mastectomy 12 (63%) 18 (95%)
Inadequate disease response 3 3
Disease progression on therapy 3 1*
Delayed wound healing post-surgery 3 (16%) 5 (26%)
*

Plus one treatment related death